GI
COLL icon

Gradient Investments’s Collegium Pharmaceutical COLL Stock Holding History

Gradient Investments’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-404
Closed -$5K – 1111
2019
Q3 		$5K Buy
+404
New +$4.61K ﹤0.01% 790

Other funds holding COLL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Gradient Investments's COLL Position: Q4 2019 in Review

Gradient Investments sold out of Collegium Pharmaceutical (COLL) in Q4 2019, closing a stake of 404 shares — an estimated $5K sold.

Gradient Investments first reported a position in COLL in Q3 2019 and held it in 1 quarter. The position peaked at $5K in Q3 2019. 138 funds tracked by Wall St. Rank hold COLL as of Q4 2019.

  • Gradient Investments reported no remaining Collegium Pharmaceutical position as of Q4 2019 after selling out during the quarter.
  • Gradient Investments sold 404 Collegium Pharmaceutical shares in Q4 2019, an estimated $5K.
  • Gradient Investments first reported a position in Collegium Pharmaceutical in Q3 2019 and held it in 1 quarter.
  • Gradient Investments's Collegium Pharmaceutical position peaked at $5K in Q3 2019.
  • 138 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q4 2019.

Based on Gradient Investments's 13F filing for Q4 2019, filed 15 Jan 2020.